Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.